Skip to main content
SpringerLink
Log in

Further information on serious ADRs resulting from denosumab [RANMARK] use*

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Daiichi Sankyo Company Limited.RANMARK SUBCUTANEOUS INJECTION 120mg (denosumab) - Risk of severe hypocalcaemia, including fatal cases. Internet Document: [5 pages], 11 Sep 2012. Available from: URL: http://www.pmda.go.jp

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Further information on serious ADRs resulting from denosumab [RANMARK] use*. React. Wkly. 1420, 4 (2012). https://doi.org/10.2165/00128415-201214200-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214200-00010

Keywords

Search

Navigation